Meiji Seika Pharma Co., Ltd. filed a Schedule 13G with the SEC on November 18, 2026, disclosing beneficial ownership of 2,466,395 shares of Arcturus Therapeutics Holdings Inc. common stock, representing 7.88% of the class, pursuant to a Securities Purchase Agreement dated November 16, 2026.
Key Highlights
- Beneficial ownership reported: Meiji Seika Pharma Co., Ltd. reported beneficial ownership of 2,466,395 shares of Arcturus Therapeutics Holdings Inc. common stock.
- Ownership percentage: The 2,466,395 shares represent 7.88% of the class, according to the filing.
- Source of shares: The shares are described as issuable to, and to be held directly by, Meiji Seika Pharma pursuant to a Securities Purchase Agreement dated November 16, 2026.
- Sole voting and dispositive power: Meiji Seika Pharma reported sole voting power and sole dispositive power over all 2,466,395 shares, with no shared voting or dispositive power.
- Share base used for calculation: The percentage is based on 28,822,514 shares outstanding as of November 3, 2026, plus the 2,466,395 issuable shares, for a total of 31,288,909 shares.
- Triggering event date: The date of the event requiring the filing is listed as November 16, 2026.
Meiji Seika Pharma's Scheduled 13G Filing and Share Position in Arcturus Therapeutics
According to the Schedule 13G filed on November 18, 2026, Meiji Seika Pharma Co., Ltd., a corporation organized in Japan and headquartered at 2-4-16, Kyobashi, Chuo-ku, Tokyo 104-8002, Japan, disclosed a beneficial ownership position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), whose principal executive offices are located at 10285 Science Center Drive, San Diego, California 92121. The filing was triggered by a Securities Purchase Agreement dated November 16, 2026, under which 2,466,395 shares of common stock, par value $0.001 per share (CUSIP 03969T109), are issuable to Meiji Seika Pharma.
The filing reports that all 2,466,395 shares reflect sole voting power and sole dispositive power held by Meiji Seika Pharma, with zero shares subject to shared voting or shared dispositive power. The percentage of class, 7.88%, was calculated using 28,822,514 shares outstanding as of November 3, 2026, as reported in Arcturus Therapeutics' Quarterly Report on Form 10-Q filed on November 5, 2026, plus the 2,466,395 issuable shares, yielding a combined total of 31,288,909 shares.
In the certification included in the filing, Meiji Seika Pharma stated that, to the best of its knowledge and belief, "the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." The statement was signed by Kenshi Murase, Director, on November 16, 2026.
What Was Disclosed
Meiji Seika Pharma Co., Ltd. filed a Schedule 13G disclosing beneficial ownership of 2,466,395 shares of Arcturus Therapeutics Holdings Inc. common stock, equal to 7.88% of the class, arising from a Securities Purchase Agreement dated November 16, 2026.



Please wait processing your request...